593 related articles for article (PubMed ID: 32390826)
1. Modeling Parkinson's Disease With the Alpha-Synuclein Protein.
Gómez-Benito M; Granado N; García-Sanz P; Michel A; Dumoulin M; Moratalla R
Front Pharmacol; 2020; 11():356. PubMed ID: 32390826
[TBL] [Abstract][Full Text] [Related]
2. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy?
De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639
[TBL] [Abstract][Full Text] [Related]
3. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
[TBL] [Abstract][Full Text] [Related]
4. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
[TBL] [Abstract][Full Text] [Related]
5. Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice.
Okuda S; Uemura N; Sawamura M; Taguchi T; Ikuno M; Uemura MT; Yamakado H; Takahashi R
Neurotherapeutics; 2022 Jan; 19(1):289-304. PubMed ID: 34935120
[TBL] [Abstract][Full Text] [Related]
6. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
7. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
8. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
9. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
10. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
11. Interaction between coxsackievirus B3 infection and α-synuclein in models of Parkinson's disease.
Park SJ; Jin U; Park SM
PLoS Pathog; 2021 Oct; 17(10):e1010018. PubMed ID: 34695168
[TBL] [Abstract][Full Text] [Related]
12. The dual role of c-src in cell-to-cell transmission of α-synuclein.
Choi YR; Kim JB; Kang SJ; Noh HR; Jou I; Joe EH; Park SM
EMBO Rep; 2020 Jul; 21(7):e48950. PubMed ID: 32372484
[TBL] [Abstract][Full Text] [Related]
13. α-Synuclein Propagation Mouse Models of Parkinson's Disease.
Uemura N; Ueda J; Okuda S; Sawamura M; Takahashi R
Methods Mol Biol; 2021; 2322():119-130. PubMed ID: 34043198
[TBL] [Abstract][Full Text] [Related]
14. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
[TBL] [Abstract][Full Text] [Related]
15. Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease.
Brembati V; Faustini G; Longhena F; Outeiro TF; Bellucci A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686236
[TBL] [Abstract][Full Text] [Related]
16. Limited spread of pathology within the brainstem of α-synuclein BAC transgenic mice inoculated with preformed fibrils into the gastrointestinal tract.
Uemura N; Yagi H; Uemura MT; Yamakado H; Takahashi R
Neurosci Lett; 2020 Jan; 716():134651. PubMed ID: 31783082
[TBL] [Abstract][Full Text] [Related]
17. Investigating the potential effects of α-synuclein aggregation on susceptibility to chronic stress in a mouse Parkinson's disease model.
Alwani A; Maziarz K; Burda G; Jankowska-Kiełtyka M; Roman A; Łyszczarz G; Er S; Barut J; Barczyk-Woźnicka O; Pyza E; Kreiner G; Nalepa I; Chmielarz P
Pharmacol Rep; 2023 Dec; 75(6):1474-1487. PubMed ID: 37725330
[TBL] [Abstract][Full Text] [Related]
18. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.
Tan Y; Sgobio C; Arzberger T; Machleid F; Tang Q; Findeis E; Tost J; Chakroun T; Gao P; Höllerhage M; Bötzel K; Herms J; Höglinger G; Koeglsperger T
Acta Neuropathol; 2020 Feb; 139(2):319-345. PubMed ID: 31768670
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
